12 March 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has yesterday resigned from the Company in order to pursue other projects. Mr Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr Hunt’s replacement and a further announcement will be made in due course.

Read more…

25 February 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at three investor events, providing an overview of the business and the progress being made by the Company as it focuses on its retinal disease programme and exosome and iPSC platforms.

Read more…

25 February 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Allenby Capital Limited (“Allenby”) as joint corporate broker, with immediate effect to work alongside the Company’s existing nominated adviser and joint broker, Stifel Nicolaus Europe Limited.

Read more…

Treatment of first patient cohort completed in Phase 2a extension of retinal disease study

15 January 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the development of its hRPC (human retinal progenitor cell) therapy candidate for retinal diseases.

Read more…

6 January 2021: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company’s recent half year results,  fundraising and outlook for the year ahead.

Read more…

17 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark Office (USPTO) has completed its examination of patent application 15/613,030, entitled: “Low oxygen culture conditions for maintaining retinal progenitor cell multipotency”, and has issued a notification of allowance for the issuance of a patent.

Read more…

11 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.

Read more…

11 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has conditionally raised total gross proceeds of approximately £2.5 million through the Open Offer announced on 23 November 2020, representing the full amount proposed under the Open Offer.

Read more…

24 November 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces, further to the announcement made on 23 November 2020 by the Company (the “Launch Announcement”), the successful completion of an oversubscribed Placing, which, together with the Subscription, has conditionally raised gross proceeds for the Company of approximately £15.0 million.

Read more…

24 November 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2020.

Read more…